Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Reposting -
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Estimated Study Completion Date:--------April 2017

ClinicalTrials.gov processed this record on April 13, 2017

[Results might be published this month. Should be positive for the shareholders.]

https://clinicaltrials.gov/ct2/show/NCT02581345

__________________________________________

Also, re: MNTA's patent application:
THERAPEUTIC AND DIAGNOSTIC METHODS FOR AUTOIMMUNE DISEASES AND/OR INFLAMMATION 2017-04-06

Studies have already been done! FDA marketing approval, next?

Excerpts -

BACKGROUND OF THE INVENTION

Anti-tumor necrosis factor-alpha (TNF-a) agents are a first-line biologic therapy in a number of autoimmune diseases. However, one third or more of the patients who initiate anti-TNFa therapy for the first time do not respond. There is a need for treatment methods for patients with autoimmune diseases and inflammations, as well as diagnostics to predict the responsiveness and non-responsiveness of patients to anti-TNFa therapies.

Sixty subjects were selected from the CERTAIN clinical trial for Fey receptor 1Mb (FcYRIIIb), Ma (FcyRlla) and Mc (FcyRMc) polymorphism analysis. This study recruited rheumatoid arthritis (RA) patients from multiple community and academic clinical centers across North America.

After the initial study, we [MNTA] further expanded the total number of subjects with rheumatoid arthritis (RA) analyzed by our methodology to a total of approximately 145.

[This covers a huge area of autoimmune and inflammatory diseases, as listed below.]

As used herein, the term "tumor necrosis factor alpha (TNF-a) mediated disease" refers to a disease or disorder involving the cytokine TNF-a. TNF-a mediated diseases include, but are not limited to, rheumatoid arthritis (RA), juvenile RA, polyarticular-course juvenile RA, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, Crohn's Disease, ulcerative colitis, ankylosing spondylitis, plague psoriasis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes, glomerulonephritis, autoimmune thyroiditis, Behcet's disease, graft rejection, and graft-versus-host disease, Kawasaki's disease, sarcoidosis, pyoderma gangrenosum, depression, bronchial asthma, diabetes mellitus, malignancies, septic shock, bullous dermatitis, neutrophilic dermatitis, toxic epidermal necrolysis, systemic vasculitis, pyoderma gangrenosum, pustular dermatitis, alcoholic hepatitis, cerebral malaria, hemolytic uremic syndrome, pre-eclampsia, allograft rejection, uveitis, otitis media, snakebite, erythema nodosum, myelodysplastic syndromes, dermatomyositis, polymyositis, immune reconstitution inflammatory syndrome of AIDS patients, systemic sclerosis, lgG4-related disease, and alopecia areata. These diseases and disorders are sometimes treated by using an anti-TNFa agent, which targets TNF-a and/or one or both of its receptors TNFR1 and TNFR2.

**For those that can decifer the scientific parlance - please read more -

https://worldwide.espacenet.com/publicationDetails/description?CC=WO&NR=2017059276A2&KC=A2&FT=D&ND=3&date=20170406&DB=EPODOC&locale=en_EP